8 recruiting. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Recruiting 8 |
| Phase 2 | 2 | Recruiting 2 |
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-10-27 |
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) Cyclophosphamide, Standard of Care (SOC), Prednisone - Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA) | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 36 | 2025-11-10 | 2026-01-30 |
| BDB-001 Phase III Trial in ANCA-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Rituximab - ANCA Associated Vasculitis (AAV) | Phase 3 | Recruiting | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 300 | 2025-11-10 | 2026-08-13 |
| Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Rituximab, Tocilizumab, Tofacitinib - Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 42 | 2025-06-06 | 2026-04-03 |
| A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases Benralizumab - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES) | Phase 3 | Recruiting | AstraZeneca | 14 | 2025-04-17 | 2026-10-28 |
| A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） SHR-1703, Mepolizumab Injection - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 166 | 2023-11-16 | 2025-12-04 |
| A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial Pioglitazone (ACTOS®), Placebo of Pioglitazone - ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 126 | 2023-10-24 | 2026-07-01 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (4) · Churg-Strauss Syndrome (3) · Granulomatosis with Polyangiitis (3) · Vasculitis (2) · Asthma (1) · Hypereosinophilic Syndrome (1) · Microscopic Polyangiitis (1)
Autoimmune Diseases (8) · Cardiovascular Diseases (8) · Immune System Diseases (8) · Skin Diseases (8) · Skin Diseases, Vascular (8) · Skin and Connective Tissue Diseases (8) · Vascular Diseases (8) · Vasculitis (6) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Granuloma (3) · Hemic and Lymphatic Diseases (3) · Lung Diseases, Interstitial (3)
Rituximab (3) · Cyclophosphamide (2) · Prednisone (2) · benralizumab (2) · Azathioprine (1) · BDB001 (1) · Pioglitazone (1) · Standard of Care (1) · avacopan (1) · mepolizumab (1) · tocilizumab (1) · tofacitinib (1)
Assistance Publique - Hôpitaux de Paris (2) · AstraZeneca (2) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Ottawa Hospital Research Institute (1) · Robert Spiera, MD (1) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (1)
France (4) · Canada (3) · United States (3) · China (2) · India (2) · Israel (2) · Netherlands (2) · Poland (2) · Turkey (Türkiye) (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Italy (1) · Mexico (1)
Alexandre Karras (1) · Benjamin Terrier, MD, PhD (1) · David Massicotte-Azarniouch, MD, MSc (1) · Lindsay Lally, MD (1) · Minghui Zhao, M.D. (1) · Robert F Spiera, MD (1)
2023 (1)